285 related articles for article (PubMed ID: 19544285)
1. Human radiolabeled mass balance studies: objectives, utilities and limitations.
Penner N; Klunk LJ; Prakash C
Biopharm Drug Dispos; 2009 May; 30(4):185-203. PubMed ID: 19544285
[TBL] [Abstract][Full Text] [Related]
2. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
[TBL] [Abstract][Full Text] [Related]
3. Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations.
Zhu M; Zhang D; Zhang H; Shyu WC
Biopharm Drug Dispos; 2009 May; 30(4):163-84. PubMed ID: 19544287
[TBL] [Abstract][Full Text] [Related]
4. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
5. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
[TBL] [Abstract][Full Text] [Related]
6. Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: a case study.
Prakash C; Li Z; Orlandi C; Klunk L
Drug Metab Dispos; 2012 Jul; 40(7):1308-20. PubMed ID: 22474055
[TBL] [Abstract][Full Text] [Related]
7. Predicting circulating human metabolites: how good are we?
Anderson S; Luffer-Atlas D; Knadler MP
Chem Res Toxicol; 2009 Feb; 22(2):243-56. PubMed ID: 19138063
[TBL] [Abstract][Full Text] [Related]
8. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
Baillie TA
Chem Res Toxicol; 2009 Feb; 22(2):263-6. PubMed ID: 19216579
[TBL] [Abstract][Full Text] [Related]
9. A holistic strategy for characterizing the safety of metabolites through drug discovery and development.
Walker D; Brady J; Dalvie D; Davis J; Dowty M; Duncan JN; Nedderman A; Obach RS; Wright P
Chem Res Toxicol; 2009 Oct; 22(10):1653-62. PubMed ID: 19715349
[TBL] [Abstract][Full Text] [Related]
10. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites.
Dalvie D; Obach RS; Kang P; Prakash C; Loi CM; Hurst S; Nedderman A; Goulet L; Smith E; Bu HZ; Smith DA
Chem Res Toxicol; 2009 Feb; 22(2):357-68. PubMed ID: 19146377
[TBL] [Abstract][Full Text] [Related]
11. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.
Tiller PR; Yu S; Bateman KP; Castro-Perez J; McIntosh IS; Kuo Y; Baillie TA
Rapid Commun Mass Spectrom; 2008 Nov; 22(22):3510-6. PubMed ID: 18853407
[TBL] [Abstract][Full Text] [Related]
12. Metabolites and safety: What are the concerns, and how should we address them?
Smith DA; Obach RS
Chem Res Toxicol; 2006 Dec; 19(12):1570-9. PubMed ID: 17173370
[TBL] [Abstract][Full Text] [Related]
13. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
[TBL] [Abstract][Full Text] [Related]
14. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?
Obach RS; Nedderman AN; Smith DA
Xenobiotica; 2012 Jan; 42(1):46-56. PubMed ID: 21992031
[TBL] [Abstract][Full Text] [Related]
15. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.
Prueksaritanont T; Lin JH; Baillie TA
Toxicol Appl Pharmacol; 2006 Dec; 217(2):143-52. PubMed ID: 17055014
[TBL] [Abstract][Full Text] [Related]
16. Interpretation and considerations on the safety evaluation of human drug metabolites.
Atrakchi AH
Chem Res Toxicol; 2009 Jul; 22(7):1217-20. PubMed ID: 19563206
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?
Penner N; Xu L; Prakash C
Chem Res Toxicol; 2012 Mar; 25(3):513-31. PubMed ID: 22309195
[TBL] [Abstract][Full Text] [Related]
18. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment.
Smith DA; Obach RS
Chem Res Toxicol; 2009 Feb; 22(2):267-79. PubMed ID: 19166333
[TBL] [Abstract][Full Text] [Related]
19. Use of radioactive compounds and autoradiography to determine drug tissue distribution.
Solon EG
Chem Res Toxicol; 2012 Mar; 25(3):543-55. PubMed ID: 22280496
[TBL] [Abstract][Full Text] [Related]
20. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.
Roffey SJ; Obach RS; Gedge JI; Smith DA
Drug Metab Rev; 2007; 39(1):17-43. PubMed ID: 17364879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
